Abstract:Background CD47,knownasintegrin-associatedreceptorprotein,isover-expressed onnon-small-celllungcancer(NSCLC)cells.Itcaninteractwithsignalregulatory protein-a(SIRPa)andinhibitmacrophagephagocytosis.Autophagy,akeyingredient in microenvironment maintenance, plays a critical role in tumorigenesis, tumor development and metastasis. Here, we report a potential approach for NSCLC therapy by targeting both CD47 and autophagy. Background ClusterofDifferentiation(CD47),knownasintegrin-associatedreceptor protein,isover-expressedonnon-small-celllungcancer(NSCLC)cells.Itcaninteract withsignalregulatoryprotein-alpha(SIRPa)andinhibitmacrophagephagocytosis. Autophagy, a key ingredient in microenvironment maintenance, plays a critical role in tumorigenesis, tumor development and metastasis. Here, we report a potential approach for NSCLC therapy by blocking both CD47 and autophagy. Methods A novel fusion protein named SIRPa-Fc was prepared and employed to target CD47onNSCLCcells.Threestandardtechniquesincludingconfocalmicroscope, transmission electron microscope and western blots were used to detect the autophagy in NSCLC cells after CD47 blockade. LDH-release and CFSE staining assay were appliedtodetectthephagocytosisofNSCLCcellsafterblockadeofCD47/autophagy. NSCLC xenograft models were established in BALB/c nude mice to investigate the anti- tumoreffectoftargetingbothCD47andautophagyinNSCLC. Methods A novel fusion protein named SIRPa-Fc was prepared and employed to block CD47onNSCLCcells.Threestandardtechniquesincludingtransmissionelectron microscope, confocal microscope and western blot were used to detect autophagy in NSCLCcellsafterCD47blockade.LDH-releaseandCFSEstainingassaywereapplied todetectthephagocytosisofNSCLCcellsafterblockadeofCD47/autophagy.NSCLC xenograft models were established in BALB/c nude mice to investigate the anti-tumor effectofblockingbothCD47andautophagyinNSCLC. Results WefoundthatblockingCD47couldincreasethephagocytosisandcytotoxicity ofmacrophageagainstNSCLCcells.Duringthisprocess,autophagywastriggered, which was characterized by the three main stages ofautophagic fluxincluding: formation and accumulation ofautophagosomes, fusion ofautophagosomes into lysosomesanddegradationofautophagosomesinlysosomes.Importantly,inhibitionof autophagyinNSCLCcellscouldnotablyenhancetheeffectofCD47blockadeon macrophage-mediatedcytotoxicity,whileco-suppressionofautophagyandCD47 signalingcouldalsoelicitpotentanti-NSCLCefficacyinvivo. Results WefoundthatblockingCD47couldincreasethephagocytosisofmacrophage against NSCLC cells. During this process, autophagy was triggered, which was characterized by the three main stages ofautophagic fluxincluding: formation andaccumulationofautophagosomes,fusionofautophagosomesintolysosomes anddegradationofautophagosomesinlysosomes.Importantly,inhibitionof autophagyinNSCLCcellscouldnotablyenhancetheeffectofCD47blockadeon macrophage-mediatedphagocytosis, whileco-suppressionofautophagyandCD47 signalingcouldalsoelicitenhancedanti-NSCLCefficacyinvivo. Conclusions We demonstrated that autophagy was induced in NSCLC cells after CD47 blockade,whileinhibitionofautophagycouldsignificantlyenhancetheanti-tumor efficacyofCD47blockadeinNSCLCs.Ourdataelucidatedthecriticalroleofautophagy inCD47abolishment-basedNSCLStherapyandhighlightedthepotentialapproachfor thetreatmentofNSCLCbyblockingautophagyandCD47. Legal entity responsible for the study N/A Funding the National Natural Science Foundation ofChina (81573332) Disclosure All authors have declared no conflicts ofinterest.

CD47-SIRPα Blockade Sensitizes Head and Neck Squamous Cell Carcinoma to Cetuximab by Enhancing Macrophage Adhesion to Cancer Cells

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

Targeting Cd47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer

Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model

CD47 Blockade Improves the Therapeutic Effect of Osimertinib in Non-Small Cell Lung Cancer.

Abstract 3727: Synergistic effect of CD47 blockade and EPHA3 treatment on recurrent head and neck cancers

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

CD47/SIRPα Blocking Peptide Identification and Synergistic Effect with Irradiation for Cancer Immunotherapy

399P Blocking CD47 and Autophagy for the Therapy of Non-Small-cell Lung Cancer

Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer

Facilitating cholangiocarcinoma inhibition by targeting CD47

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma

Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody

Deciphering the role of CD47 in cancer immunotherapy

Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy

Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47

Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T-Cell Lymphoma

Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy

Co-targeting CD47 and VEGF Elicited Potent Antitumor Effects in Gastric Cancer